Low Level Laser Therapy as an adjuvant therapy for Duchenne muscular dystrophy

Lidiane Begalli de Souza1, Mariana Cruz Lazzarin1, Flavia de Oliveira1*

1Departamento de Biociências, Universidade Federal de São Paulo, Campus Baixada Santista, SP, Brazil

Duchenne muscular dystrophy (DMD) is a rare disease caused by mutations or rearrangements in the dystrophin gene, leading to progressive muscle lesion. There is no curative treatment for DMD, however, there is evidence that treatment with LLLT acts to decrease inflammation, oxidative stress, pain and stimulate muscle repair. The aim of this review was to discuss the effects of LLLT as a helpful alternative therapy to be associated with other treatments for DMD. To this end, a systematic research in PubMed database was conducted including the following terms: “Duchenne muscular dystrophy” and “low level laser therapy” or “mdx mice” and “low level laser therapy”. After prospecting scientific articles, 5 were selected. As a result, it was found that there is a lack of information about the use of LLLT on DMD patients because all of the studies were preclinical. The selected articles showed that mdx mice were chosen as the experimental model and although they describe the positive effects of LLLT, the studies were performed with different mice ages, parameters of irradiation, treatment duration and muscle chosen. In conclusion, according to this review both preclinical animal experiments and human clinical studies with LLLT use should be expanded to the benefits of patients in this translational research answer.

Duchenne muscular dystrophy (DMD) is a recessive disease associated with the X chromosome, caused by mutations or rearrangements in the dystrophin gene, a structural protein belonging to the dystrophin-glycoprotein complex1, and the global DMD birth prevalence is 1 per 100,000 live male births2. The dystrophin-glycoprotein complex is responsible for stabilizing the cytoskeleton of muscle fibers with the extracellular matrix3. The absence of dystrophin leads the muscle to lesions characterized by progressive degeneration, inflammatory infiltration and fibrosis4. The sarcolemma's fragility due to the absence of dystrophin worsens with physiological events such as calcium influx and oxidative stress5. In addition, with the progression of the disease, repeated degenerative- regenerative cycles impaired regeneration, resulting in the replacement of muscle fibers by connective tissue6. The loss of muscle regenerative capacity is accompanied by an increased fibrogenesis leading to muscular tissue to be replaced by fibrotic tissue7. Among the various pathophysiological mechanisms proposed in DMD, evidence suggests the involvement of inflammation8 and oxidative stress to explain the dystrophic process9,10.

Low Level Laser Therapy (LLLT) has non-thermal therapeutic effects and has been used in some inflammatory diseases in order to provide a non-invasive treatment strategy due to the photochemical effects, which act on the cell membrane, being able to alter cellular functions in irradiated cells11,12. It has been shown that the phototherapy can promote the biochemical adaptation of the mitochondria with changes in the redox state, leading to a conversion of electromagnetic energy into biochemistry, consequently, increasing oxygen consumption, ATP production and respiratory rate13,11. Evidence from experimental investigations suggests that LLLT promotes skeletal muscle regeneration by reducing the duration of acute inflammation and accelerating tissue repair11. According to Ferraresi et al.14 the use of LLLT has expanded to cover areas of medicine. Besides the usual applications in wound healing and inflammatory orthopedic conditions, the ability of LLLT for reducing or repairing the consequences of muscle fatigue, stimulate muscle repair in addition to reduce inflammation and oxidative stress, should be expanded. Furthermore, LLLT represents a cost-effective therapy for musculoskeletal pain15.

There is no curative treatment for Duchenne muscular dystrophy. However, there is evidence that treatment with LLLT acts to decrease inflammation, oxidative stress, pain and stimulate muscle repair. In this context, the aim of this review was to discuss the effects of LLLT as a helpful alternative therapy to be associated with other treatment for DMD.

During the searches of this study, was conducted systematic research in the PubMed database (National Library of Medicine and National Institutes of Health). The MeSH terms used as keywords were: “Duchenne muscular dystrophy” and “low level laser therapy” or “mdx mice” and “low level laser therapy”.

As an inclusion criterion, during the search, the title and summary were read and verified according to the aim of this study. The following duplications articles or not therapeutic use of laser or literature review, were not included in the present investigation.

Original research articles and written in English were included. No geographical exclusion criteria were imposed. Selected articles were from the period between 2014 and 2018, due to the lack of studies before 2014. The presentation of the results followed the criteria of the publication's chronological order: from the oldest to the most recent. Finally, the discussion of the articles was based on the clinical importance of the LLLT in Duchenne muscular dystrophy.

After prospecting scientific articles using the descriptors already mentioned for this review, 6 articles were found. Out of 6 screened scientific publications, 5 were selected and fully reviewed. All selected studies were preclinical, with mdx mice. The only scientific article excluded was a literature review.

No clinical study was found with DMD and LLLT and, although no geographical exclusion criteria have been imposed in this research, most of studies have been carried out in Brazil, except the study by Oron et al.17, carried out in Israel. Due to a variety of information found about aim of study, LLLT parameters and mice age, the results were distributed in a Table, according to the mice age, descriptions of irradiation parameters, study aim and main conclusion (Table 1).

Table 1. Main information about the use of LLLT in Duchenne muscular dystrophy
Author/ experimental model, age LLLT parameters Study Aim Main Conclusion
Leal-Junior et al.16 / mdx mice/six weeks Superpulsed LLLT administered using a wavelength of 904 nm, light density 52W/cm2, 10,4W power and dose of 1 J on successive days, 5 times per week for 14 weeks To evaluate effects of preventive treatment with LLLT on progression of dystrophy in mdx mice, assessing skeletal muscle morphology, skeletal muscle damage and inflammation. LLLT effects ameliorated morphological changes, skeletal muscle damage and inflammation in mdx mice. This suggests that LLLT may decrease progression of DMD.
Oron et al. 17/ mdx mice,1 week Ga-Al-As diode laser (810 nm), applied at a power density of 10 mW/cm2 to the surface (area of 0.0255 cm2 ) of hindlimb muscle for 120 sec (fluence of 1.2 J/cm2 ) once a week for 4 consecutive weeks To determine whether low-level laser therapy (LLLT) at early stages postpartum could affect regeneration and degenerative processes in skeletal muscles of the dystrophic mdx mouse. LLLT applied to mdx mice during postnatal development may have a significant beneficial effect in the induction of regenerative capacity and reduction of degenerative muscle foci in these mice, with possible direct clinical relevance.
Silva et al.18/ mdx mice,1 week LLLT administered using a wavelength of 808 nm, output power 30mW, power density 1071W/cm2 , spot size 0.028cm2 and and dose of 3 J, 3 consecutive days. To verify whether the levels of oxidative stress markers could be influenced by LLLT in mdx mice subjected to high-intensity exercise training on an electric treadmill. LLLT was able to reduce oxidative stress markers these markers even in conditions of muscle fatigue; LLLT also reduced the levels of antioxidant enzyme markers significantly; LLLT had a beneficial effect on the skeletal muscle of mdx mice and improved the performance of these animals. However, the single application of LLLT and the dose parameters used were not able to cause changes in the morphology of dystrophic muscles.
Macedo et al.19/ Primary cultures of mdx skeletal muscle cells Aluminum Gallium Arsenide (AIGaAs) diode, 830 nm wavelength at 5 J/cm2 fluence, continuous emission during 20 seconds, 30mW output cm2 power and 0.07 For after 24h and 48h Evaluated LLLT effects on some physiological pathways that may lead to muscle damage or regeneration capacity in dystrophin-deficient muscle cells of mdx mice, the experimental model of DMD. LLLT improved regenerative capacity and decreased inflammatory response and oxidative stress in dystrophic muscle cells culture.
Albuquerque- Pontes et al.20/ mdx mice, 6 weeks Photobiomodulati on Therapy (PBMT) with doses of 1 J , 3 J, and 10 J. PBMT was performed employing a cluster probe with 9 diodes (1 x 905nm super- pulsed laser diode; 4 x 875nm infrared LEDs; and 4 x 640nm red LEDs, 3 times a week for 14 weeks To test the effects of different doses of PBMT on muscle morphology, gene and protein expression of dystrophin, and on functional performance of DMDmdx mice. PBMT had positive effects on dystrophic skeletal muscle and delayed disease progression. This therapy may have a protective effect when applied at the onset of DMD.

In DMD disease, considering that there is no effective therapy available, there are many treatments aiming to improve patients’ quality of life and delaying the progression of the disease, such as induced pluripotent stem cells as a powerful technology in drug discovery21, pharmacological agents that slow the progression of the disease22 and motor physical therapy23. Numerous pre-clinical models, such as mice, rats, dogs, pigs and rabbit have advantages and disadvantages24, but it is important to highlight that, although the contribution of different treatment strategies to prolong ambulation and provide improvements in quality of life and life expectancy, they do not provide a definitive cure. The most used experimental preclinical model for investigating the pathophysiology of DMD is the mouse of the mdx lineage (X-chromosome linked muscular dystrophy). In mdx mice, the mutation occurs due to a premature stop codon, resulting in termination in exon 23 of the dystrophin gene25.

Taken together, the aim of this review was to discuss the effects of LLLT as an adjuvant therapy to improve quality of life in DMD. Although the positive effects of LLLT intervention on the inflammation and oxidative stress, there is a lack of information about the interaction of LLLT on Duchenne muscular dystrophy in humans because the majority of studies are preclinical. The only study with laser therapy in humans with DMD seen was by Abdel et al.26 that verified the role of He-Ne laser irradiation in ameliorating blood oxidative stress in DMD patients vs. controls. It is important to highlight that, in this study, the blood DMD samples were irradiated with He-Ne laser, but not skeletal muscle.

The selected articles for this review showed that mdx mice were chosen as experimental model and in different ages. This is an important point in mdx model because signs such as necrosis, central nuclei cells and inflammatory infiltrate of muscle degeneration and regeneration, vary according to the animal age. Considering that, the histopathological events change, and the more serious stage occurs with 26 weeks27. In addition to differences in age criteria, several methods were used for irradiation parameters, number of irradiation points, treatment duration and muscle chosen.

It is well known that the most part of LLLT studies is in local and acute inflammation process. The biggest challenge of LLLT treatment in DMD is the chronic and systemic condition, i.e., although the preclinical studies show the effects of LLLT in specific skeletal muscles, DMD affects the muscular system. In this way, which muscle to choose? Maybe muscles related to locomotion, but, how many points are necessary to apply in groups of locomotion muscle? For LLLT to be effective, the irradiation parameters need to be within certain ranges according to the treatment goal. Ferraresi et al.14 presented a literature review about the use of LLLT on human muscle tissue and showed clinical trials with acute or chronic responses and numerous parameters that answer these questions and, in conclusion of review, they encourage researchers to investigate the effects of LLLT on patients with Duchenne muscular dystrophy. The concept of translational research reinforces this idea. According to Callard et al.28 translational research aims to translate findings from basic research more quickly and efficiently into clinical and health-care practice: in other words, such research is intended to ease the path from laboratory experiments through to clinical trials to patient.

Regarding possible adverse effects in LLLT, according to Cotler el al.15 “The North American Association for Laser Therapy conference in 2010” held a consensus meeting on safety and contraindications. The study summarizes main contraindications such as exposure of the eyes, carcinogenesis in patients, pregnancy, epileptic and photosensitivity. Therefore, a careful evaluation history is fundamental to the LLLT pre-use in DMD patients.

In conclusion, based on positive effects LLLT verified in preclinical studies and the importance of laboratory experiments through to clinical trials to interventions, studies about LLLT in human DMD patients are necessary for the contribution of different treatment strategies to prolong ambulation and provide improvements in quality of life in DMD patients. Therefore, according to this review both preclinical animal experiments and human clinical studies with LLLT should be expanded to the benefits of patients in this translational research answer.

The authors declare that they have no conflict of interest.

  1. Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: the protein product of theDuchenne muscular dystrophy locus. Cell. 1987;51(6):919-28. doi:10.1016/0092-8674(87)90579-4.
  2. Crisafulli S, Sultana J, Fontana A, et al. Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-nalysis. Orphanet J Rare Dis. 2020;15(1):141. doi:10.1186/s13023-020-01430-8
  3. Lapidos KA, Kakkar R, McNally EM. The dystrophin glycoprotein complex: signaling strength and integrity for the sarcolemma. Circ Res. 2004;94(8):1023-1031. doi:10.1161/01.RES.0000126574.61061.25
  4. 't Hoen PA, van der Wees CG, Aartsma-Rus A, et al. Gene expression profiling to monitor therapeutic and adverse effects of antisense therapies for Duchenne muscular dystrophy. Pharmacogenomics. 2006;7(3):281-297. doi:10.2217/14622416.7.3.281
  5. Espinosa A, Henríquez-Olguin C, Jaimovich E. Reactive oxygen species and calcium signals in skeletal muscle: A crosstalk involved in both normal signaling and disease. Cell Calcium. 2016;60(3):172-179. doi:10.1016/j.ceca.2016.02.010
  6. Deconinck N, Dan B. Pathophysiology of duchenne muscular dystrophy: current hypotheses. Pediatr Neurol. 2007;36(1):1-7. doi:10.1016/j.pediatrneurol.2006.09.016
  7. Arecco N, Clarke CJ, Jones FK, et al. Elastase levels and activity are increased in dystrophic muscle and impair myoblast cell survival, proliferation and differentiation. Sci Rep. 2016;6:24708. Published 2016 May 31. doi:10.1038/srep24708
  8. Hnia K, Hugon G, Rivier F, et al. Modulation of p38 mitogen- activated protein kinase cascade and metalloproteinase activity in diaphragm muscle in response to free radical scavenger administration in dystrophin-deficient Mdx mice. Am J Pathol. 2007;170(2):633-643. doi:10.2353/ajpath.2007.060344
  9. Chahbouni M, Escames G, Venegas C, et al. Melatonin treatment normalizes plasma pro- inflammatory cytokines and nitrosative/oxidative stress in patients suffering from Duchenne muscular dystrophy. J Pineal Res. 2010;48(3):282-289. doi:10.1111/j.1600- 079X.2010.00752.x
  10. Souza LB, Maziero C, Lazzarin MC, et al. Presence of metalloproteinases 2 and 9 and 8- OHdG in the fibrotic process in skeletal muscle of Mdx mice. Acta Histochem. 2020;122(1):151458. doi:10.1016/j.acthis.2019.151458
  11. da Silveira Campos RM, Damaso AR, Masquio DC, et al. Low-level laser therapy (LLLT) associated with aerobic plus resistance training to improve inflammatory biomarkers in obese adults. Lasers Med Sci. 2015;30(5):1553-1563. doi:10.1007/s10103-015-1759-9
  12. Fabre HS, Navarro RL, Oltramari-Navarro PV, et al. Anti-inflammatory and analgesic effects of low-level laser therapy on the postoperative healing process. J Phys Ther Sci. 2015;27(6):1645-1648. doi:10.1589/jpts.27.1645
  13. Karu T, Pyatibrat L, Kalendo G. Irradiation with He-Ne laser increases ATP level in cells cultivated in vitro. J Photochem Photobiol B. 1995;27(3):219-223. doi:10.1016/1011- 1344(94)07078-3
  14. Ferraresi C, Hamblin MR, Parizotto NA. Low-level laser (light) therapy (LLLT) on muscle tissue: performance, fatigue and repair benefited by the power of light. Photonics Lasers Med. 2012;1(4):267-286. doi:10.1515/plm-2012-0032
  15. Cotler HB, Chow RT, Hamblin MR, et al. The Use of Low Level Laser Therapy (LLLT) For Musculoskeletal Pain. MOJ Orthop Rheumatol. 2015;2(5):00068. doi:10.15406/mojor.2015.02.00068
  16. Leal-Junior EC, de Almeida P, Tomazoni SS, et al. Superpulsed low-level laser therapy protects skeletal muscle of mdx mice against damage, inflammation and morphological changes delaying dystrophy progression. PLoS One. 2014;9(3):e89453. Published 2014 Mar 5. doi:10.1371/journal.pone.0089453
  17. Oron A, Oron U, Sadeh M. Low-level laser therapy during postnatal development modulates degeneration and enhances regeneration processes in the hindlimb muscles of dystrophic mice. Photomed Laser Surg. 2014;32(11):606-611. doi:10.1089/pho.2014.3757
  18. Silva AA, Leal-Junior EC, D'Avila Kde A, et al. Pre-exercise low-level laser therapy improves performance and levels of oxidative stress markers in mdx mice subjected to muscle fatigue by high-intensity exercise. Lasers Med Sci. 2015;30(6):1719-1727. doi:10.1007/s10103-015-1777-7
  19. Macedo AB, Moraes LH, Mizobuti DS, et al. Low-Level Laser Therapy (LLLT) in Dystrophin- Deficient Muscle Cells: Effects on Regeneration Capacity, Inflammation Response and Oxidative Stress. PLoS One. 2015;10(6):e0128567. Published 2015 Jun 17. doi:10.1371/journal.pone.0128567
  20. Albuquerque-Pontes GM, Casalechi HL, Tomazoni SS, et al. Photobiomodulation therapy protects skeletal muscle and improves muscular function of mdx mice in a dose- dependent manner through modulation of dystrophin. Lasers Med Sci. 2018;33(4):755-764. doi:10.1007/s10103-017-2405- 5
  21. Danisovic L, Culenova M, Csobonyeiova M. Induced Pluripotent Stem Cells for Duchenne Muscular Dystrophy Modeling and Therapy. Cells. 2018;7(12):253. doi: 10.3390/cells7120253.
  22. Guiraud S, Davies KE. Pharmacological advances for treatment in Duchenne muscular dystrophy.CurrOpinPharmacol. 2017;34:36-48. doi:0.1016/j.coph.2017.04.002.
  23. Kostek M. Precision Medicine and Exercise Therapy in Duchenne Muscular Dystrophy. Sports. 2019;7(3):64. doi: 10.3390/sports7030064.
  24. Wells DJ. Tracking progress: an update on animal models for Duchenne muscular dystrophy. Dis Model Mech. 2018;11(6):dmm035774. Published 2018 Jun 13. doi:10.1242/dmm.035774
  25. Grounds MD, Radley HG, Lynch GS, et al. Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy. Neurobiol Dis. 2008;31(1):1-19. doi:10.1016/j.nbd.2008.03.008
  26. Abdel SE, Abdel-Meguid I, Korraa S. Markers of oxidative stress and aging in Duchene muscular dystrophy patients and the possible ameliorating effect of He:Ne laser. Acta Myol. 2007;26(1):14-21.
  27. Gillis JM. Understanding dystrophinopathies: an inventory of the structural and functional consequences of the absence of dystrophin in muscles of the mdx mouse. J Muscle Res Cell Motil. 1999;20(7):605-625. doi:10.1023/a:1005545325254
  28. Callard F, Rose D, Wykes T. Close to the bench as well as at the bedside: involving service users in all phases of translational research. Health Expect. 2012;15(4):389-400. doi:10.1111/j.1369-7625.2011.00681.x

Article Info

Article Notes

  • Published on: July 05, 2020


  • Mdx mice

  • Low Level Laser Therapy
  • Duchenne muscular dystrophy
  • Rehabilitation


Flavia de Oliveira
Departamento de Biociencias, Universidade Federal de Sao Paulo – UNIFESP, Rua Silva Jardim, 136 – Lab 328 - CEP: 11015-020 - Santos – SP, Brasil. Phone: +55 13 3878-3844
Email: flavia.oliveira@unifesp.br

©2020 De Souza LB. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License.